On 6 December 2012, orphan designation (EU/3/12/1073) was granted by the European Commission to Bayer Pharma AG, Germany, for maytansinoid-conjugated human monoclonal antibody against mesothelin for the treatment of mesothelioma.
The sponsorship was transferred to Bayer AG, Germany, in August 2017.
This medicine is now known as anetumab ravtansine.
Maytansinoid-conjugated human monoclonal antibody against mesothelin (anetumab ravtansine)
|Disease / condition||
Treatment of malignant mesothelioma
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.